Navigation Links
Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays

Agilent Technologies Inc. (NYSE: A) today announced that it has for the first time released the chip design, probe sequence and annotation information for all of its microarrays. The release of this information is expected to improve cross-laboratory experimental research and cross-platform data comparison.

"Full release of the probe sequences is an admirable and responsible position for Agilent to take," said Catherine Ball, president of the Microarray Gene Expression Data (MGED) Society and director of the Stanford Microarray Database. "Rigorous science requires that others be able to easily interpret and verify or contradict one's work. With this sequence information, the research community will be better equipped to interpret data generated with Agilent arrays and to determine confidence in these data in future years, when genomic sequences may have been updated. In that sense, release of these sequences makes the results of experiments using Agilent arrays far more valuable."

This announcement is being made in conjunction with the extensive release of microarray experimental data into the public domain by the National Toxicology Program. Icoria Inc., under its contract with the National Institute of Environmental Health Sciences (NIEHS), has been using Agilent microarrays to perform thousands of experiments to profile chemical effects on biological systems, thereby creating a vast resource of gene expression responses to chemical toxicants. The data will eventually be made available through the NIEHS National Center of Toxicogenomics' Chemical Effects on Biological Systems (CEBS) database, currently under development.

"The NIEHS National Center for Toxicogenomics is very pleased that Agilent has released the probe sequences for its gene expression microarrays to the public domain," said Michael Waters, Ph.D., assistant director for database development of the NCT. "The availability of these sequences will be of great benefit to the microa
'"/>

Source:Agilent


Page: 1 2

Related biology news :

1. Agilent Technologies releases automated literature search tool for biology researchers
2. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
3. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
4. Agilent Technologies introduces advanced zebrafish, mouse microarrays for stem cell and developmental biology research
5. Agilent Technologies introduces high-capacity human protein removal system for proteomics research
6. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
7. MSI releases moleculizer - a new approach to simulation of intracellular biochemical networks
8. Center releases new public survey on stem cells
9. DOE JGI releases IMG 1.5 with curated archaeal genomes
10. DOE JGI sequences, releases genome of symbiotic tree fungus
11. Triple threat polymer captures and releases
Post Your Comments:
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... -- (July 29, 2009) -- Italian and U.S. biologists this ... rare genetic disorder plays an unexpected and critical role in ... in the journal Nature shows that the protein, ... a previously undocumented way. "If you,d asked me a ...
... obesity have tripled in the last 25 years, putting many ... a report in Academic Pediatrics by an obesity ... Baptist Medical Center. "Children are not only becoming ... said Joseph Skelton, M.D., lead author and director of the ...
... is a longtime user of the Advanced Light Source ... to major advances in lensless imaging. It,s a particularly ... they can,t be focused with ordinary lenses. ... in faster pulses, lensless imaging becomes ever more critical ...
Cached Biology News:Little-known protein found to be key player 2Research shows rates of severe childhood obesity have tripled 2Jet-propelled imaging for an ultrafast light source 2Jet-propelled imaging for an ultrafast light source 3Jet-propelled imaging for an ultrafast light source 4Jet-propelled imaging for an ultrafast light source 5Jet-propelled imaging for an ultrafast light source 6
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... SYDNEY , July 29, 2015 US-Australian ... NVGN ) today confirmed it is committed to progressing ... as soon as practicable and to ensure the Company ... Chief Executive Officer, Iain Ross , said the ... including the lead pre-clinical programs, discovery programs and academic ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... August 15 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... in the acquisition, development and,commercialization of therapeutics for ... and hepatitis C, today announced its,financial results for ... At June 30, 2007, the Company had cash, ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), ... period under,Hart-Scott-Rodino Antitrust Improvements Act of 1976 with ... BETA 3) from Renovo Group plc,(LSE: RNVO) expired ... terms, the,License Agreement became effective on August 15, ...
... Amyris Co-founder Recognized for Role in Engineering Microbes to Produce ... TR35 2007 Recipients to be Honored at Technology Review,s ... ... Amyris Biotechnologies is,pleased to announce that Neil Renninger, Ph.D., ...
Cached Biology Technology:XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 2XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 4XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 5XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 6XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 7XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 8XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 9XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 10XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 11XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 12XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 13XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 14Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 2Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 3
... Application: For the efficient enrichment of ... tissue or cell culture. The isolated ... degradation and metabolic pathway analysis. Metabolic ... deficiency in children, cystic fibrosis and ...
Plasmid expressing the LacZ reporter gene....
... PYREX Fernbach-style culture flasks have triple baffles ... bottom to achieve maximal oxygen transfer to ... marking spot., A wide range of optional ... Polypropylene colored caps for ease of ...
...
Biology Products: